chikungunya
viru
chikv
etiolog
agent
chikungunya
fever
chikf
arthropodborn
diseas
transmit
mainli
aed
genu
speci
weaver
first
describ
presentday
tanzania
earli
chikf
case
treat
dengu
viru
denv
infect
lumsden
follow
isol
chikv
infect
patient
sera
well
ae
stegomyia
aegypti
linnaeu
culex
spp
mosquito
viru
place
arboviru
group
ross
calish
karabatso
current
chikv
group
within
alphaviru
genu
togavirida
famili
identifi
member
semliki
forest
viru
sfv
antigen
complex
van
duijlricht
et
al
ictv
shortli
identif
east
africa
chikv
describ
central
southern
region
africa
uganda
sub
urban
sylvat
chikv
transmiss
cycl
describ
caglioti
et
al
sylvat
cycl
especi
africa
may
involv
particip
aed
speci
aed
furcif
edward
aed
taylori
edward
aed
luteocephalu
newstead
et
al
aed
vittatu
bigot
aed
fulgen
edward
differ
nonhuman
primat
nhp
speci
possibl
reservoir
amplifi
host
chikv
eg
african
green
monkey
chlorocebu
sabaeu
linnaeu
pata
monkey
erythrocebu
pata
schreber
guinea
baboon
papio
papio
desmarest
guenon
cercopithecu
aethiop
linnaeu
bushbabi
galago
senegalensi
geoffroy
mandril
mandrillu
sphinx
linnaeu
redtail
monkey
cercopithecu
ascaniu
schmidti
matschi
chacma
baboon
papio
ursinu
kerr
mcintosh
mccrae
et
al
diallo
et
al
chevillon
et
al
pruetz
et
al
caglioti
et
al
kade
et
al
althous
et
al
vector
role
also
suggest
culex
anophel
mosquito
found
infect
seneg
diallo
et
al
urban
cycl
ae
aegypti
ae
albopictu
known
main
vector
weaver
current
probabl
remain
main
vector
chikv
transmiss
america
africa
europ
asia
oceania
horwood
et
al
et
al
zeller
et
al
ngoagouni
et
al
significantli
ae
aegypti
also
main
vector
virus
zikv
denv
cotransmiss
event
may
observ
et
al
howev
demonstr
simultan
infect
denvchikvzikv
denvchikv
ae
aegypti
compromis
vector
compet
le
coupanec
et
al
et
al
known
horizont
transmiss
chikv
aed
mosquito
occur
act
posit
mainten
infect
cycl
fig
maval
et
al
vertic
transmiss
chikv
aed
also
observ
natur
experiment
condit
pinpoint
possibl
reason
viral
persist
harsh
environment
condit
fig
agarw
et
al
chompoosri
et
al
jain
et
al
insid
arthropod
vector
chikv
must
replic
reach
mosquito
salivari
gland
within
roughli
seven
ten
day
transmiss
suscept
human
lim
et
al
fig
human
host
intrins
incub
time
vari
one
twelv
day
infect
individu
may
present
viremia
ten
day
kam
et
al
simon
et
al
azevedo
et
al
maternalfet
transmiss
also
report
human
fig
neonat
enceph
consequ
vertic
transmiss
observ
instanc
brazilian
epidem
bandeira
et
al
lyra
et
al
howev
breast
milk
transmiss
evidenc
patterson
et
al
despit
fact
chikv
rna
detect
semen
even
day
post
symptom
onset
indic
possibl
transmiss
via
sexual
intercours
horizont
transmiss
human
yet
report
fig
bandeira
et
al
patterson
et
al
approxim
individu
infect
chikv
develop
clinic
diseas
fever
arthralgia
stapl
et
al
ayu
et
al
nakkhara
et
al
chikv
infect
associ
sudden
onset
febril
ill
patient
arthralgia
patient
back
pain
patient
headach
patient
fatigu
thibervil
et
al
common
symptom
chikf
polyarthralgia
typic
bilater
polyarticular
natur
affect
mainli
peripher
joint
ankl
wrist
phalang
larg
joint
knee
elbow
morrison
cutan
manifest
report
circa
acut
case
lesion
character
macular
transitori
maculopapular
erupt
edemat
itchi
often
occur
bodi
extrem
palm
sole
feet
torso
face
simon
et
al
thibervil
et
al
gastrointestin
symptom
diarrhea
vomit
nausea
abdomin
pain
occur
case
acut
phase
thibervil
et
al
possibl
symptom
includ
erythema
asthenia
conjunctiv
effus
persist
conjunct
cervic
lymphadenopathi
stapl
et
al
stapl
fischer
madariaga
et
al
differ
studi
demonstr
chikv
infect
reach
high
viral
load
rang
copi
viral
rnaml
seem
correl
presenc
sever
clinic
sign
symptom
chow
et
al
appassakij
et
al
polyarthralgia
andor
polyarthr
hallmark
symptom
chronic
chikungunya
mostli
affect
small
joint
phalang
wrist
well
larg
joint
eg
ankl
knee
shoulder
condit
usual
sever
lead
mobil
limit
afflict
patient
hoarau
et
al
polyarthralgia
describ
persist
vari
period
time
last
week
sever
month
case
five
year
depend
popul
evalu
borgherini
et
al
sissoko
et
al
manimunda
et
al
simon
et
al
persist
polyarthralgia
alphavirus
sfv
sinv
seem
associ
persist
viral
antigen
immun
respons
inflamm
joint
atkinson
et
al
perri
et
al
hoarau
et
al
labadi
et
al
simon
et
al
poo
et
al
silva
dermodi
viral
antigen
still
consensu
whether
replic
compet
perhap
mutat
promot
persist
result
delay
clearanc
nonrepl
viral
antigen
atkinson
et
al
perri
et
al
poo
et
al
weaver
lecuit
precis
chikv
studi
describ
presenc
macrophag
chikv
genet
materi
viral
protein
synovi
tissu
chronic
infect
patient
hoarau
et
al
experiment
studi
shown
chikv
persist
lymphoid
organ
liver
joint
muscl
macrophag
nhp
labadi
et
al
addit
presenc
infiltr
cell
mainli
macrophag
monocyt
lymphocyt
specif
proinflammatori
mediat
within
synovi
fluid
probabl
also
contribut
chronic
inflamm
chikungunya
diseas
silva
dermodi
moreov
sever
case
chikungunya
may
relat
age
divers
underli
medic
condit
hypertens
respiratori
condit
diabet
mellitu
borgherini
et
al
borgherini
et
al
sankari
et
al
economopoul
et
al
sissoko
et
al
tandal
et
al
pathogenesi
rheumatoid
arthriti
chikf
still
debat
certain
studi
suggest
viral
infect
may
trigger
initi
chronic
inflammatori
disord
studi
find
inflammatori
marker
infect
individu
chronic
symptom
stapl
et
al
schilt
et
al
chikv
infect
also
lead
atyp
clinic
manifest
syndrom
gb
instanc
associ
chikv
infect
lebrun
et
al
oehler
et
al
gb
compris
acut
inflammatori
demyelin
polyneuropathi
global
incid
twothird
case
occur
bacteri
eg
campylobact
jejuni
heikema
et
al
viral
infect
oehler
et
al
dengu
simon
et
al
west
nile
lei
stokic
influenza
choi
yeon
cytomegalo
steger
et
al
human
immunodefici
girgin
et
al
epsteinbarr
phillip
kim
et
al
zika
virus
et
al
recent
chikv
outbreak
total
partial
alopecia
head
bodi
predomin
femal
patient
ophthalmolog
alter
uveiti
retin
describ
chronic
phase
infect
et
al
cunha
trinta
newborn
congenit
infect
may
accompani
vari
clinic
sign
fever
lack
appetit
apnea
skin
manifest
distal
cerebr
edema
enceph
hemorrhag
gopakumar
ramachandran
bandeira
et
al
lyra
et
al
heartand
gastrointestin
disord
cutan
lesion
report
manifest
two
day
onset
fever
chikvinfect
newborn
children
ernould
et
al
bullou
lesion
associ
chikv
infect
also
report
fourmonthold
babi
bodi
surfac
affect
second
day
onset
fever
robin
et
al
death
chikv
infect
previous
consid
rare
event
percept
howev
chang
sinc
latest
epidem
present
consider
increas
mortal
rate
probabl
due
neurolog
affect
mainli
neonat
immunocompromis
elderli
rampal
et
al
kee
et
al
chusri
et
al
bandeira
et
al
challeng
differenti
clinic
sign
symptom
chikv
infect
patholog
especi
zikv
denv
cocircul
geograph
region
hua
comb
individu
infect
arbovirus
present
wide
rang
similar
clinic
manifest
rash
myalgia
exanthema
arthralgia
joint
pain
headach
lymph
node
hypertrophi
neurolog
impair
fever
brito
cordeiro
addit
difficult
determin
frequenc
intens
symptom
correctli
assess
pain
mild
moder
intens
afflict
patient
tabl
context
variat
clinic
present
case
give
hint
viral
etiolog
instanc
salient
prolong
polyarthralgia
often
accompani
rash
typic
indic
chikungunya
hemorrhag
manifest
myalgia
commonli
observ
denv
infect
lee
et
al
despit
patient
coinfect
chikvdenv
chikvzikv
chikvdenvzikv
often
show
exacerb
clinic
sign
coinfect
present
addit
obstacl
differenti
diagnosi
furuyakanamori
et
al
et
al
et
al
tabl
summar
clinic
laboratori
featur
evalu
effici
differenti
diagnosi
chikv
denv
zikv
infect
sinc
varieti
intens
symptom
associ
chikv
denv
zikv
infect
similar
make
clinic
diagnosi
difficult
area
cocircul
laboratori
analysi
necessari
confirm
respect
viral
etiolog
hematolog
find
associ
chikv
infect
commonli
either
unspecif
howev
lymphopenia
hypocalcemia
frequent
observ
sever
thrombocytopenia
rare
borgherini
et
al
brito
cordeiro
paho
moreov
creactiv
protein
gener
elev
acut
phase
ill
tabl
venugopalan
et
al
brito
cordeiro
paho
elev
hepat
enzym
well
elev
creatinin
creatin
phosphokinas
level
also
report
danislozano
et
al
differ
laboratori
pattern
observ
chikv
denv
zikv
infect
ad
clinic
find
may
incorpor
support
correct
diagnosi
tabl
laboratori
test
specif
diagnosi
chikv
infect
base
viru
isol
viral
rna
detect
serolog
johnson
et
al
despit
usual
employ
routin
diagnosi
viral
isol
perform
sera
collect
seven
day
onset
ill
inocul
mosquitoor
mammalian
cell
line
cytopath
effect
appear
one
three
day
inocul
confirm
result
possibl
via
immunofluoresc
rtpcr
assay
pan
et
al
stapl
et
al
dash
et
al
recent
immunochromatograph
assay
use
antichikv
monoclon
antibodi
detect
differ
chikv
genotyp
sampl
acut
infect
patient
highli
specif
sensit
assay
may
also
altern
method
chikv
infect
diagnosi
okabayashi
et
al
molecular
method
chikv
diagnosi
rtpcr
rtlamp
qrtpcr
gain
increas
import
sensit
faster
viral
isol
permit
rna
detect
chikv
lineag
high
specif
usual
serum
sampl
collect
seven
day
symptomonset
suitabl
chikv
detect
molecular
diagnost
platform
edward
et
al
litzba
et
al
sharma
et
al
addit
novel
multiplex
assay
capabl
differenti
chikv
infecti
agent
similar
clinic
spectrum
among
rtlamp
assay
shown
capabl
differenti
zikv
chikv
denv
infect
yaren
et
al
rtqpcr
capabl
success
differenti
zikvchikvdenv
chikvdenvleptospira
infect
also
recent
describ
pabbaraju
et
al
giri
et
al
later
phase
infect
chikv
detect
usual
base
serolog
method
elisa
plaqu
reduct
neutral
test
prnt
elisa
techniqu
use
distinguish
acut
convalesc
infect
via
detect
antichikv
igm
igg
antibodi
igm
detect
twofour
day
three
month
onset
ill
igg
detect
sever
year
grivard
et
al
pialoux
et
al
reddi
et
al
moreov
elisa
chikv
diagnosi
highli
specif
high
accuraci
johnson
et
al
igm
antibodycaptur
elisa
macelisa
via
igm
antibodi
detect
serum
sampl
collect
four
day
onset
symptom
tabl
signal
symptom
may
contribut
differenti
diagnosi
dengu
chikungunya
zika
ill
commonli
use
test
laboratorybas
diagnos
reddi
et
al
prnt
use
paramet
measur
circul
neutral
antibodi
use
establish
immunoprotect
level
base
determin
serum
antibodi
titer
requir
neutral
known
amount
infecti
viru
particl
azami
et
al
altern
techniqu
antichikv
antibodi
detect
includ
immunofluoresc
hemagglutin
inhibit
stapl
et
al
gener
suitabl
etiolog
diagnosi
reach
combin
epidemiolog
clinic
laboratori
approach
perform
experienc
health
profession
algorithmguid
infograph
specif
laboratori
key
find
use
differenti
diagnosi
chikv
denv
andor
zikv
infect
summar
fig
chikungunya
dengu
zika
fever
rash
b
c
licens
specif
antivir
avail
control
chikv
replic
thu
therapeut
strategi
must
support
symptomat
includ
fluid
intak
jain
et
al
kaur
chu
context
nonsteroid
antiinflammatori
drug
nsaid
paracetamol
indic
reduc
fever
reliev
arthralg
pain
howev
nsaid
interfer
secondari
level
platelet
aggreg
mechan
blood
clot
eg
aspirin
avoid
goupil
more
coadministr
nsaid
lowdos
system
corticosteroid
recommend
reduc
pain
improv
qualiti
life
treat
acut
chikungunya
case
arthralgia
padmakumar
et
al
past
concern
corticosteroid
treatment
may
exacerb
alphavir
arthritid
appear
unjustifi
sinc
serodiagnosi
demonstr
antivir
immun
mylona
et
al
succinct
overview
current
strategi
inhibit
chikv
infect
recent
publish
subudhi
et
al
briefli
among
antichikv
drug
evalu
prepar
target
viral
adsorpt
fusion
translat
viral
protein
genom
replic
mainli
viral
nonstructur
protein
matur
viral
glycoprotein
immunolog
molecul
brighton
briolant
et
al
molecular
test
neg
serolog
test
must
perform
perform
serolog
test
sampl
collect
day
onset
clinic
sign
symptom
prnt
requir
due
crossreact
denv
zikv
test
also
flaviviru
eg
west
nile
saint
loui
enceph
virus
refer
cdc
paho
drug
compound
evalu
treatment
chikv
infect
licens
malaria
treatment
antivir
activ
alreadi
demonstr
hiv
sarscov
b
sfv
pilot
studi
shown
chloroquin
could
employ
treatment
arthralgia
chronic
chikungunya
howev
use
acut
phase
still
debat
studi
also
shown
increas
viral
replic
sfv
ecmv
treatment
chloroquin
brighton
de
lamballeri
et
al
maheshwari
srikanta
bhartiyaet
khan
et
al
arbidol
inhibit
fusion
viru
particl
plasma
membran
viru
particl
membran
endosom
silymarin
reduct
chikv
replic
effici
downregul
viral
protein
involv
replic
silymarin
interfer
postentri
stage
chikv
infect
reduc
dose
depend
manner
protein
product
lani
et
al
ribavirin
probabl
inhibit
viral
mrna
polymeras
bind
nucleotid
bind
site
enzym
antivir
licens
treatment
rsv
f
hcv
g
patient
drug
group
report
improv
joint
pain
soft
tissu
swell
also
reduc
togeth
abl
inhibit
chikv
sfv
replic
vero
cell
ravichandran
manian
palumbo
turner
et
al
briolant
et
al
decanoylrvkrchloromethyl
keton
decrvkrcmk
inhibit
matur
glycoprotein
inhibit
furin
wichit
et
al
exampl
drug
compound
evalu
avail
tabl
absenc
therapeut
strategi
licens
vaccin
effici
vector
control
play
crucial
role
chikv
prevent
huang
et
al
unfortun
uncontrol
urban
lack
proper
basic
sanit
increas
resist
variou
class
insecticid
challeng
true
impact
vector
control
measur
reduct
arboviru
incid
resnik
liang
et
al
overcom
obstacl
integr
antiviru
control
requir
includ
epidemiolog
surveil
b
environment
manag
focus
educ
action
elimin
potenti
mosquito
breed
site
reduc
stand
water
site
c
chemic
control
use
repel
mainli
travel
pregnant
women
insecticid
respect
vector
resist
biolog
control
egg
larva
mosquito
fig
hemingway
ranson
dumont
chiroleu
benelli
islam
et
al
benelli
last
context
larvivor
fish
belong
genu
gambusia
eg
gambusia
affini
baird
girard
poecilia
eg
poecilia
reticulata
peter
suggest
sever
countri
region
mosquito
control
mainli
ae
aegypti
hoy
da
prasad
cavalcanti
et
al
walton
chandra
et
al
seng
et
al
dumont
chiroleu
kweka
et
al
kamareddin
shuls
et
al
pereira
oliveira
chobu
et
al
natur
mosquito
predat
includ
copepod
eg
mesocyclop
thermocyclopoid
harada
mesocyclop
longisetu
invertebr
aquat
organ
also
implement
success
reduc
ae
aegypti
culicida
popul
rawlin
et
al
manriquesaid
et
al
vu
et
al
schaper
mahesh
kumar
et
al
benelli
pavela
plantborn
molecul
shown
activ
aed
anophel
culex
larval
instar
recent
approach
base
green
synthes
nanoparticl
suggest
use
denv
ae
aegypti
vector
madhiyazhagan
et
al
sujitha
et
al
microbiolog
intervent
use
bacillu
thuringiensi
var
israelensi
bti
berlin
entomopathogen
fungi
eg
metarhizium
anisoplia
metschnikoff
sorokin
beauveria
bassiana
balsamo
vuillemin
shown
effect
malaria
mosquito
well
ae
aegypti
ae
albopictu
novak
et
al
blanford
et
al
armengol
et
al
knol
et
al
lam
et
al
ritchi
et
al
paula
et
al
b
recent
bti
use
prevent
zikv
transmiss
continent
unit
state
stoddard
anoth
promis
approach
arboviru
control
includ
also
zikv
releas
wolbachiainfect
male
mosquito
steril
mosquito
insect
carri
domin
lethal
gene
use
reduc
ae
aegypti
ae
albopictu
popul
fig
ferreira
et
al
alphey
et
al
walker
et
al
boyer
alphey
et
al
massonnetbruneel
et
al
lee
et
al
zhang
et
al
b
dicken
et
al
despit
theoret
basi
effect
addit
studi
need
verifi
true
risk
benefit
program
base
alter
mosquito
concern
appear
greater
relat
transgen
mosquito
especi
efficaci
sustain
impact
environ
target
nontarget
speci
wilk
et
al
although
mani
strategi
initi
direct
denv
applic
transmiss
control
chikv
consid
mainli
within
integr
approach
ration
combin
differ
measur
control
program
insectborn
diseas
malaria
benelli
beier
also
serv
model
chikv
prevent
synergist
way
mass
immun
chikv
would
import
tool
viral
control
prophylaxi
sever
distinct
vaccin
approach
current
develop
howev
vaccin
licens
antichikv
candid
alreadi
test
human
andor
anim
includ
inactiv
attenu
viru
like
particl
vlp
dnaand
chimer
vaccin
eckel
et
al
levitt
et
al
muthumani
et
al
wang
et
al
tiwari
et
al
sharma
et
al
akahata
et
al
plant
et
al
wang
et
al
gorchakov
et
al
brandler
et
al
chang
et
al
et
al
tretyakova
et
al
van
den
doel
et
al
erasmu
et
al
past
viral
inactiv
strategi
first
test
cours
antichikv
vaccin
develop
chikv
replic
cell
cultur
subsequ
inactiv
formalin
ether
iodonapthyl
azid
ina
abl
stimul
product
neutral
antibodi
eckel
et
al
tiwari
et
al
sharma
et
al
particularli
use
ina
result
reduc
bind
capac
neutral
antibodi
sharma
et
al
formalin
inactiv
stimul
cellular
immun
respons
product
antiand
proinflammatori
cytokin
tiwari
et
al
aim
outlin
virul
chikv
infect
brandler
et
al
report
recombin
liveattenu
measl
vaccin
express
vlp
compos
capsid
c
envelop
e
protein
la
chikv
strain
ecsa
lineag
mice
suscept
measl
viru
mv
immun
mvchikv
induc
high
titer
chikv
antibodi
specif
cellular
immun
respons
protect
anim
lethal
chikv
challeng
brandler
et
al
phase
clinic
trial
european
clinic
trial
databas
manag
integr
aed
vector
control
use
insecticid
repel
carri
take
account
mosquito
resist
profil
import
consid
evalu
influenc
intervent
ecosystem
balanc
second
vaccin
result
seroconvers
particip
immunogen
mvchikv
affect
preexist
antimv
immun
vaccinationrel
seriou
advers
effect
record
ramsauer
et
al
also
use
vaccin
platform
vlpbase
akahata
et
al
propos
use
vaccin
vlp
express
chikv
structur
protein
vlpbase
vaccin
obtain
transfect
plasmid
express
c
e
protein
chikv
strain
wa
lineag
vaccin
stimul
product
neutral
antibodi
e
protein
differ
chikv
strain
abl
protect
challeng
monkey
test
human
show
vaccin
efficaci
immunogen
without
report
arthralgia
side
effect
chang
et
al
one
develop
strategi
current
undergo
phase
ii
clinic
trial
nation
clinic
trial
anoth
approach
chikv
vaccin
develop
use
dna
vaccin
context
plasmid
express
consensu
sequenc
c
chikv
protein
elicit
robust
cellular
immun
respons
product
high
antibodi
titer
capabl
recogn
wild
viru
antigen
muthumani
et
al
anoth
studi
mice
immun
dna
vaccin
contain
complet
chikv
genom
strain
develop
neutral
antibodi
protect
neurovirul
chikv
tretyakova
et
al
strategi
involv
inactiv
virus
vlp
dna
vaccin
often
stimul
humor
immun
respons
one
main
mechan
control
prevent
chikv
infect
lum
et
al
empiricallyor
reverseengin
attenu
live
vaccin
howev
shown
capabl
induc
cellular
humor
immun
respons
also
suggest
prevent
chikv
infect
levitt
et
al
wang
et
al
wang
et
al
plant
et
al
gorchakov
et
al
et
al
import
exampl
attenu
chikv
vaccin
vaccin
base
empir
attenu
chikv
strain
asian
lineag
isol
patient
sera
chikv
outbreak
thailand
levitt
et
al
end
phase
ii
clinic
trial
evalu
vaccin
individu
present
neutral
antibodi
remain
seroconvert
one
year
present
temporari
arthralgia
edelman
et
al
addit
classic
attenu
via
serial
viral
passag
cell
revers
genet
strategi
employ
platform
construct
recombin
attenu
virus
vaccin
chimera
wang
et
al
plant
et
al
wang
et
al
et
al
van
den
doel
et
al
erasmu
et
al
antichikv
strategi
involv
develop
attenu
chimer
vaccin
use
intern
ribosom
entri
site
ire
encephalomyocard
viru
ecmv
approach
chikv
subgenom
promot
strain
ecsa
lineag
knock
via
insert
synonym
mutat
ecmv
ire
sequenc
ad
new
promot
subgenom
rna
transcript
plant
et
al
briefli
addit
ire
sequenc
attenu
viral
genom
prevent
viral
propag
mosquito
cell
thu
restrict
target
popul
vaccin
strategi
shown
lead
stimul
respons
mice
plant
et
al
nhp
chikvir
vaccin
also
show
safe
immunogen
effect
roy
et
al
final
preclin
safeti
chikvir
vaccin
ensur
receptorincompet
mice
mice
plant
et
al
viral
chimera
propos
context
antichikv
vaccin
strategi
notabl
attenu
strain
eastern
equin
enceph
viru
veev
eastern
equin
enceph
viru
eeev
use
backbon
express
chikv
structur
protein
creat
immunogen
chimera
abl
stimul
product
neutral
antibodi
protect
mice
diseas
viremia
chikv
challeng
wang
et
al
anoth
chimer
construct
modifi
vaccinia
ankara
express
glycoprotein
protein
shown
stimul
product
neutral
antibodi
ifni
ifn
ii
receptor
knockout
mice
mice
protect
lethal
infect
van
den
doel
et
al
replicationincompet
adenoviru
vector
also
use
express
orf
code
chikv
structur
polyprotein
singl
dose
chimera
induc
high
antibodi
titer
capabl
neutral
asian
iol
chikv
lineag
protect
mice
viremia
arthralgia
recent
promis
vaccin
base
chimera
eilat
viru
eilv
chikv
report
erasmu
et
al
eliv
chikv
possess
nonstructur
protein
eilv
structur
accessori
protein
chikv
strain
asian
lineag
sinc
eilv
alphaviru
specif
insect
eilvchikv
unabl
replic
vertebr
host
therebi
provid
high
degre
safeti
nhp
elivchikv
stimul
immun
respons
guarante
protect
viremia
erasmu
et
al
last
decad
increas
dissemin
cocircul
sever
arbovirus
current
area
endem
denv
instanc
autochthon
case
chikungunya
zika
diseas
arbovirus
similar
clinic
spectrum
requir
effici
laboratori
diagnosi
especi
rigor
epidemiolog
surveil
addit
chikv
infect
repres
seriou
public
health
problem
high
morbid
chikungunya
often
result
absente
afflict
individu
incur
psychosoci
econom
impact
context
develop
specif
antichikv
drug
certainli
import
demand
hand
ideal
control
strategi
chikv
combin
integr
vector
manag
mass
immun
although
differ
vector
biocontrol
strategi
promis
mainli
within
integr
use
necessari
think
sustain
use
assess
real
impact
ecosystem
equilibrium
absenc
chikv
serotyp
consid
facilit
aspect
antichikv
vaccin
develop
sinc
formul
develop
one
strain
like
result
immun
chikv
smalley
et
al
despit
recent
advanc
vaccin
strategi
major
challeng
regard
chikv
vaccin
develop
remain
establish
equilibrium
immunogen
safeti
notabl
reduct
side
effect
secondari
arthralgia
follow
immun
attenu
viru
final
recogn
compet
vector
arbovirus
control
measur
believ
prevent
chikv
infect
plan
within
global
multifactori
approach
interdisciplinari
strategi
current
frame
within
one
health
concept
thu
integr
aspect
health
care
human
anim
environ
benelli
duggan
author
conflict
interest
disclos
acknowledg
ef
oliveirafilho
r
support
de
amparo
e
tecnologia
estado
de
pernambuco
facep
mctcnpq
dcr
grant
jvj
silva
support
de
de
pessoal
de
superior
cape
trr
lope
support
conselho
nacion
de
desenvolvimento
e
cnpq
